Last reviewed · How we verify

NCT05250245

Tolterodine Relieves Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea Syndrome

Completed Phase 4 Last updated 22 February 2022
What this trial tests

Phase 4 trial testing Tolterodine Tartrate 4 MG in Overactive Bladder in 60 participants. Completed in 1 January 2022.

Timeline
1 June 2020
Primary endpoint
30 December 2021
1 January 2022

Quick facts

Lead sponsorYuzuncu Yil University
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment60
Start date1 June 2020
Primary completion30 December 2021
Estimated completion1 January 2022
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Yuzuncu Yil University

Who can join

Adults 18 to 60, female only, with Overactive Bladder or Obstructive Sleep Apnea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, we aim to determine whether combined tolterodine and CPAP therapy is a more effective treatment for patients with OSAS than CPAP treatment only.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Overactive Bladder

Currently open trials in the same condition.

Other Yuzuncu Yil University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05250245.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing